AR067425A1 - Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u - Google Patents
Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su uInfo
- Publication number
- AR067425A1 AR067425A1 ARP080104064A ARP080104064A AR067425A1 AR 067425 A1 AR067425 A1 AR 067425A1 AR P080104064 A ARP080104064 A AR P080104064A AR P080104064 A ARP080104064 A AR P080104064A AR 067425 A1 AR067425 A1 AR 067425A1
- Authority
- AR
- Argentina
- Prior art keywords
- bcg
- cepa
- proteins
- calmette
- guerin
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 239000012634 fragment Substances 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000186359 Mycobacterium Species 0.000 title abstract 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 238000004690 coupled electron pair approximation Methods 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 abstract 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 abstract 1
- 102100024407 Jouberin Human genes 0.000 abstract 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
El fragmento inmunogénico de las cepas de VRS subtipo A y VRS subtipo B, proveniente de las proteínas NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F o G. El material genético que codifica para estas proteínas o fragmentos se encuentra inserto en el genoma de BCG o de manera extracromosomal en una o varias copias, cuya expresion está comandada por promotores endogenos o exogenos de BCG, constituidos o inducibles. Las proteínas o fragmentos inmunogénicos virales pueden ser expresados por BCG de forma soluble-citoplasmática, secretada extracelularmente o como proteínas unidas a membrana celular. La preparacion puede contener además combinaciones de formulaciones descritas anteriormente. La formulacion puede ser estabilizada por liofilizacion (rango de conservacion entre 4sC y 25sC) o por temperatura (-80sC) en una solucion salina tampon para ser conservada previo a su uso. Reivindicacion 1: Formulacion inmunogénica que confiere proteccion contra la infeccion o patología causada por el virus respiratorio sincicial caracterizada porque comprende cepa recombinante atenuada de Mycobacterium, preferentemente la cepa Bacilo de Calmette y Guerin (BCG), en una concentracion entre 104 - 109 bacterias, que expresa al menos una proteína o fragmento inmunogénico del virus respiratorio sincicial (VRS), en una solucion tampon salina farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2007002710A CL2007002710A1 (es) | 2007-09-20 | 2007-09-20 | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067425A1 true AR067425A1 (es) | 2009-10-14 |
Family
ID=51399051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104064A AR067425A1 (es) | 2007-09-20 | 2008-09-18 | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u |
| ARP190101676A AR116662A2 (es) | 2007-09-20 | 2019-06-18 | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101676A AR116662A2 (es) | 2007-09-20 | 2019-06-18 | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8398993B2 (es) |
| EP (1) | EP2207567B1 (es) |
| CN (1) | CN101918029B (es) |
| AR (2) | AR067425A1 (es) |
| CL (1) | CL2007002710A1 (es) |
| DK (1) | DK2207567T3 (es) |
| ES (1) | ES2528197T3 (es) |
| PE (1) | PE20090653A1 (es) |
| PL (1) | PL2207567T3 (es) |
| WO (1) | WO2009039178A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102021149B (zh) * | 2010-07-27 | 2013-04-24 | 张卫东 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
| AU2013245950B2 (en) * | 2012-04-10 | 2016-04-21 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| CL2013002829A1 (es) * | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| BR112016028816A8 (pt) | 2014-06-13 | 2021-07-20 | Glaxosmithkline Biologicals Sa | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório |
| CN104593389A (zh) * | 2015-01-27 | 2015-05-06 | 吉林大学 | 一种重组合胞病毒蛋白及其应用 |
| CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
| CL2020000857A1 (es) | 2020-03-31 | 2021-11-05 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína del virus respiratorio sincicial humano contra bvrs en bovinos |
| CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566121B1 (en) * | 1991-06-13 | 2003-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | Insertional mutations in mycobacteria |
| EP0590027A4 (en) * | 1991-06-13 | 1994-10-19 | Einstein Coll Med | INSERTION MUTATIONS IN MYCOBACTERIA. |
| US20020081317A1 (en) * | 1999-02-02 | 2002-06-27 | Mahan Michael J. | Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope |
| US20040022800A1 (en) * | 2000-07-31 | 2004-02-05 | Mark Parrington | Respiratory syncytial virus vaccine |
| EP1404368B1 (en) * | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US7070786B2 (en) * | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| US20060115494A1 (en) * | 2004-12-01 | 2006-06-01 | Ronggai Sun | Recombinant BCG strains with attenuated immunosuppressive properties |
-
2007
- 2007-09-20 CL CL2007002710A patent/CL2007002710A1/es unknown
-
2008
- 2008-09-17 CN CN200880114324.0A patent/CN101918029B/zh active Active
- 2008-09-17 DK DK08832386.0T patent/DK2207567T3/en active
- 2008-09-17 WO PCT/US2008/076682 patent/WO2009039178A1/en not_active Ceased
- 2008-09-17 US US12/679,091 patent/US8398993B2/en active Active - Reinstated
- 2008-09-17 PL PL08832386T patent/PL2207567T3/pl unknown
- 2008-09-17 ES ES08832386.0T patent/ES2528197T3/es active Active
- 2008-09-17 EP EP08832386.0A patent/EP2207567B1/en active Active
- 2008-09-18 AR ARP080104064A patent/AR067425A1/es not_active Application Discontinuation
- 2008-09-18 PE PE2008001628A patent/PE20090653A1/es active IP Right Grant
-
2019
- 2019-06-18 AR ARP190101676A patent/AR116662A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR116662A2 (es) | 2021-06-02 |
| EP2207567B1 (en) | 2014-11-05 |
| WO2009039178A1 (en) | 2009-03-26 |
| DK2207567T3 (en) | 2015-01-26 |
| EP2207567A4 (en) | 2013-05-01 |
| CN101918029B (zh) | 2015-05-20 |
| PE20090653A1 (es) | 2009-06-20 |
| US8398993B2 (en) | 2013-03-19 |
| PL2207567T3 (pl) | 2015-06-30 |
| CL2007002710A1 (es) | 2008-01-04 |
| CN101918029A (zh) | 2010-12-15 |
| EP2207567A1 (en) | 2010-07-21 |
| US20110200634A1 (en) | 2011-08-18 |
| ES2528197T3 (es) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067425A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u | |
| CN102127533B (zh) | 重组猪圆环病毒2型Cap抗原的制备方法 | |
| Pusch et al. | Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin | |
| AR065076A1 (es) | Vacuna contra el papilomavirus | |
| WO2013039861A3 (en) | Engineered nucleic acids and methods of use thereof | |
| PH12015500773B1 (en) | Methods and compositions for live attenuated viruses | |
| Aggarwal et al. | Immunological priming requires regulatory T cells and IL-10–producing macrophages to accelerate resolution from severe lung inflammation | |
| JP2015525572A5 (es) | ||
| WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
| JP2011504366A5 (es) | ||
| WO2012075379A3 (en) | Liquid viral formulations | |
| WO2009036341A3 (en) | Compositions and methods relating to hiv protease inhibition | |
| Drake et al. | Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N | |
| WO2009063503A3 (en) | Process for purification of human tissue type plasminogen activator | |
| CN111518163A (zh) | 一类脂肽化合物在抗新型冠状病毒中的应用 | |
| Bąska et al. | Excretory/secretory products of Fasciola hepatica but not recombinant phosphoglycerate kinase induce death of human hepatocyte cells | |
| WO2022155482A9 (en) | Aav vectors targeting t-cells | |
| BRPI0720874C1 (pt) | composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica | |
| WO2013072917A3 (en) | Antiviral composition | |
| AR085800A1 (es) | Vacuna de rinitis equina | |
| Du et al. | Construction, expression and antiviral activity analysis of recombinant adenovirus expressing human IFITM3 in vitro | |
| NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella | |
| PE20250795A1 (es) | Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia | |
| CN104356220B (zh) | 一种具有血小板聚集抑制功能的抗hiv白纹伊蚊蛋白及其制备方法 | |
| PE20221731A1 (es) | NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |